Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 214 posts found.

White blood cells

CHMP recommend white blood cell growth stimulator biosimilar to EMA

July 30, 2018
Sales and Marketing Amgen, CHMP, EMA, Neulasta, biosimilar, chemotherapy, pegfilgrastim

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate …

News
sean-harper

Amgen announces resignation of two top executives

July 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper

Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …

Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra

With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …

News
fda2outsideweb

FDA approves Pfizer biosimilar version of Amgen’s Neupogen

July 23, 2018
Sales and Marketing Amgen, FDA, Neupogen, Nivestym, Pfizer, pharma

The FDA has announced its decision to approve Pfizer’s Nivestym, the firm’s biosimilar version of Amgen’s Neupogen (filgrastim), for use …

News
amgen_hq

Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis

June 27, 2018
Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …

News
mylan_inside_0

Mylan lands biosimilar sucker punch to Amgen’s blockbuster

June 6, 2018
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta

Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …

News
novartis_side_building

Amgen/Novartis migraine med gets CHMP nod

June 4, 2018
Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …

News
headache

Amgen/Novartis potential blockbuster migraine med gets FDA nod

May 18, 2018
Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …

News
amgen_hq

Europe expands approved indication of Amgen’s Repatha in cardiovascular disease

May 17, 2018
Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News
john_tsai

Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head

April 19, 2018
Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma

Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …

News
amgen_flag

Amgen and Novartis’ Aimovig shines in migraine at Phase 3

April 18, 2018
Research and Development Aimovig, Amgen, Novartis, migraine, pharma

Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …

News
shutterstock_141105490

Uncovering trends in the future of real world data

March 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, feature, pharma, real world data, real world evidence

A new report has canvassed the intentions of industry players in the use of real world data and evidence over …

Feature
allergan-westport-ireland_web

New breakthrough for CGRP migraine treatments

February 6, 2018
Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical

Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …

News
amgen_flag

FDA clears Amgen’s bone drug for multiple myeloma

January 8, 2018
Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma

Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023